Primary source: Download the Final Guidance Document
Immediate implementation of guidance prohibiting the use of clove oil, isoeugenol, and methyleugenol as anesthetics in fish, referencing that these products are not approved new animal drugs.
This guidance addresses potential human food safety and animal food safety risks, highlighting carcinogenic components of clove oil. It delineates the approved alternatives for fish anesthesia, which are critical for maintaining food safety standards.
Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.
Regulatory Intelligence Lead
Monitor for updates on regulations or guidance related to fish anesthetics.
Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.
The FDA issued Guidance Document CVM GFI #150 which outlines significant concerns regarding the use of clove oil as an anesthetic for fish, stating that it has not been approved for such use and may pose safety risks.
What changed: Immediate implementation of guidance prohibiting the use of clove oil, isoeugenol, and methyleugenol as anesthetics in fish, referencing that these products are not approved new animal drugs.
Why it matters: This guidance addresses potential human food safety and animal food safety risks, highlighting carcinogenic components of clove oil. It delineates the approved alternatives for fish anesthesia, which are critical for maintaining food safety standards.
Practical implication: Regulatory intelligence teams must update workflows to exclude clove oil as an anesthetic for fish and ensure compliance with the guidance, including awareness of approved alternatives.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Clinical investigations must now include justification for DDM selection and ensure that DHTs are verified and validated to support their intended clinical role.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
